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STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit
and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases
of classical Hodgkin’s disease. Proliferation of L1236 cells was neither affected by addition of stem cell factor nor by
neutralising anti-stem cell factor antibodies or STI571. Results suggest that patients with Hodgkin’s disease may not beneﬁt
from therapy with STI571.
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The malignant cells in classical Hodgkin’s disease (cHD), the
Hodgkin and Reed Sternberg cells (H-RS), are mostly derived from
germinal centre B-cells as indicated by somatic mutations within
their rearranged immunoglobulin genes (Ku ¨ppers and Rajewsky,
1998). Nevertheless, H-RS cells phenotypically exert several charac-
teristics not typical for B-cells. They lack expression of most B-cell
speciﬁc proteins (Drexler, 1992) and, instead, express proteins
restricted to other lineages or to immature precursor cells (Coss-
man et al, 1998). Expression of c-kit as a marker of an
immature phenotype, for instance, has been described in H-RS cells
in cHD previously (Pinto et al, 1994).
The tyrosine kinase inhibitor STI571 has been shown to selec-
tively inhibit the receptor tyrosine kinases v-abl and bcr–abl, the
platelet derived growth factor receptor (PDGFR) and the receptor
for the stem cell factor, i.e. c-kit (Druker et al, 1996; Buchdunger
et al, 2000; Heinrich et al, 2000). This speciﬁc activity of STI571
is already exploited for tumour control in chronic myelogeneous
leukaemia (Druker et al, 2001) and soft tissue sarcomas (Joensuu
et al, 2001). It recently has been proposed (Buchdunger et al,
2000) that STI571 may also be effective in other malignancies
expressing receptors for PDGF or c-kit. We here evaluate the
expression of c-kit in HD derived cell lines and cases of cHD in
order to test the therapeutic potential of STI571 for cHD.
MATERIALS AND METHODS
Cell lines and pathological specimen
The characteristics of the six HD derived cell lines are summarised
by Drexler (1993) and Wolf et al (1996). L1309 is an EBV immor-
talised lymphoblastoid cell line from a healthy donor. M07e is a
myeloid leukaemia cell line purchased at DSMZ (Braunschweig,
Germany). Twenty primary cases of classical HD (seven mixed
cellularity, nine nodular sclerosis, two lymphocyte depleted, two
lymphocyte rich classical) and a case of gastrointestinal mesenchy-
mal stromal tumour were analysed by immunohistochemistry.
Immunohistochemistry was performed on parafﬁn embedded
formalin-ﬁxed specimen according to standard protocols using a
polyclonal rabbit anti-human c-kit antibody (DAKO, Hamburg,
Germany).
Flow cytometry
Hodgkin’s disease derived cell lines were incubated with a
phycoerythrin conjugated mouse anti-human CD117 monoclonal
antibody (clone 95C3; AnDerGrub, Austria) following the instruc-
tions of the manufacturer and analysed on a Becton-Dickinson
FACS Calibur.
Proliferation assay
Hodgkin’s disease derived cell lines and LCL1309 were plated in
96-well ﬂat bottom culture plates at a density of 20000 cells per
well. M07e cells were plated at 50000 cells per well and cultured
in the presence of stem cell factor (SCF) (200 ng ml
71; R&D,
Germany). Recombinant human SCF, neutralising anti-human
SCF antibody (dissolved in phosphate buffered saline; R&D) or
STI571 (dissolved in DMSO; provided by Dr Elizabeth Buchdun-
ger, Novartis Pharma, Basel, Switzerland) was added according to
the respective experimental setup. At 48 h MTT was added to each
well and cells were lysed after 2 h following the instructions of the
manufacturer (TACS assay; R&D).
Polymerase chain reaction and sequence analysis
High molecular weight DNA was extracted from L1236 cells
according to standard protocols. Ampliﬁcation and sequencing
of exon 11 and 17 was performed at 558C as described
previously (Re et al, 2001) using published oligonucleotides (Tian
et al, 1999).
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Amounts of SCF were quantiﬁed in 24 h supernatants from cell
lines using a commercially available ELISA kit (Quantakine; R&D).
RESULTS AND DISCUSSION
Analysis of c-kit and SCF expression in HD derived cell
lines
Using FACS analysis, a strong cell surface expression of c-kit
was detected in the HD derived cell line L1236 while c-kit
expression was absent in ﬁve other HD derived cell lines
(L428, KM-H2, L591, Hdlm-2, L540) (Table 1). Secretion of
the c-kit ligand SCF was tested in the supernatant of all six
HD derived cell lines and controls. Low amounts of SCF were
detected in L1236 and M07e cell cultures (53 and 30 pg ml
71,
respectively). Detection of both SCF and c-kit in L1236 cells
suggested an autocrine mechanism of growth control in L1236
cells.
Treatment of HD-derived cell lines with SCF, anti-SCF
antibodies and STI571
In order to further characterise the postulated autocrine role of the
c-kit/SCF interaction for proliferation and viability of L1236 cells, a
MTT (dimethylthiazol–diphenyltetrazolium bromide) based assay
was performed with L1236 cells and controls (M07e was used for
positive control and cell lines L428 and LCL1309 for negative
control). As shown in Figure 1A, addition of SCF to cell cultures
stimulated growth of control cells M07e but not of L1236 cells.
Accordingly, after addition of a neutralising anti-SCF antibody to
the cell cultures, proliferation of M07e but not of L1236 cells
was inhibited (Figure 1B).
Mutant constitutively active c-kit receptors that are found e.g.
in mast cell disease (Longley et al, 1996) may cause an SCF
independent proliferation of c-kit expressing cells. Since these
activating c-kit mutations mostly have been detected in exon
11 and exon 17, we performed L1236 DNA sequence analysis
of c-kit exon 11 and 17 (GenBank accession number 1817732:
base pair 75662–75788 and 81257–81463). These experiments
revealed germ line conﬁguration of both exons (data not
shown). It is thus concluded, that SCF independence of
L1236 proliferation is unlikely to be due to DNA mutations
of the c-kit gene.
When cells were treated with the tyrosine kinase inhibitor
STI571, positive controls but not H-RS cells showed a marked
decrease of c-kit dependent proliferation at STI571 doses of 0.1
to 1 mmol l
71 (Figure 1C). With increasing doses of STI571,
L1236 cells as well as negative controls L428 and LCL1309 showed
reduction of proliferation rate possibly due to unspeciﬁc toxic
effects.
Immunostaining of H-RS cells in situ for c-kit expression
Twenty primary cases of cHD were immunostained using a mono-
clonal antibody speciﬁc for c-kit. A gastrointestinal mesenchymal
stromal tumour with known strong cell surface expression of c-
kit (Hirota et al, 1998) was used as positive control. Absence of
c-kit expression was found in H-RS cells of all twenty cases. This
negative result was somewhat surprising as Pinto et al (1994)
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Table 1 Expression of c-kit and SCF in L1236 H-RS cells is suggestive for
an autocrine mechanism
CD117 SCF (pg ml
71)
M07e + 30
L1236 + 53
L428, KM-H2, L591, L540, Hdlm2 77
LCL1309 77
Summary of CD 117 (c-kit) expression and stem cell factor (SCF) secretion in the
myeloid leukaemia cell line M07e, six HD derived cell lines and a lymphoblastoid cell
line (LCL). (+) indicates that 490% of cells stains positive for CD117, (7) indicates
that 490% of cells stain negative for CD117. Mean value of SCF secretion was deter-
mined in 2–3 experiments each performed in duplicate.
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Figure 1 Proliferation of c-kit positive L1236 cells is not inﬂuenced upon
stimulation with SCF, anti-SCF antibodies or the c-kit inhibitor STI571.
Forty-eight-hours MTT proliferation assay with the HD derived cell lines
L1236 (c-kit
+/SCF
+) and L428 (c-kit
7/SCF
7), the lymphoblastoid cell line
1309 (c-kit
7/SCF
7) as negative control and the myeloid cell line M07e (c-
kit
+/SCF
+) as postivie control. Incubation of cell lines with increasing doses
of (A) stem cell factor (SCF); (B) neutralising anti-SCF antibody; (C) tyro-
sine kinase inhibitor STI571. Each experiment was performed in triplicate
and repeated at least three times. Mean value of proliferation and single
standard deviation of representative experiments are shown.
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out of 17 cases of cHD. The c-kit receptor protein expression was
selectively detected in cases of cHD and anaplastic large cell
lymphoma while it was absent in cases of non-Hodgkin’s lympho-
ma. It therefore has been speculated, that c-kit may be activated in
an autocrine or paracrine fashion and regulate growth of c-kit
expressing neoplastic cells. In contrast, our results suggest, that
H-RS cells commonly do not express c-kit. These immunohisto-
chemical analyses are well conceivable with our in vitro
experiments suggesting, that activation of c-kit is not even involved
in control of proliferation of c-kit positive H-RS cells of the cell
line L1236. It is therefore concluded, that administration of the
c-kit inhibitor STI571 may not be beneﬁcial for patients with cHD.
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